Risdiplam Archives -

Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

https://pharmaphorum.com/news/nice-reaches-a-deal-with-roche-on-access-to-oral-sma-drug-evrysdi/

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance,

NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group

https://pharmaphorum.com/news/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group/

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market

Novartis pulls rival to Roche’s risdiplam in SMA, says market limited

https://pharmaphorum.com/news/novartis-pulls-rival-to-roches-risdiplam-in-sma-says-market-limited/

The FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision

FDA cues up May verdict for Roche’s SMA challenger risdiplam

https://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/

Risdiplam